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ABSTRACT
Cardioprotective Effects of Mitochondrial-Targeted Antioxidants
in Myocardial Ischemia/Reperfusion (I/R) Injury
Reactive oxygen species (ROS) generated during myocardial I/R contribute to
post-reperfused cardiac contractile dysfunction. Damaged cardiomyocyte
mitochondria are major sites of excess ROS generation during reperfusion.
We hypothesized that reducing mitochondrial ROS formation should attenuate
myocardial I/R injury and thereby improve function of isolated perfused rat
hearts subjected to I(30min)/R(45min) compared to untreated I/R hearts.
Mitoquinone (MitoQ, MW=579g/mol; complexed with cyclodextrin
(MW=1135g/mol) to improve water solubility, total MW=1714g/mol), a
coenzyme Q derivative, and SS-31 (Szeto-Schiller) peptide ((D-Arg)-Dmt-LysPhe-Amide, MW=639g/mol, Genemed Synthesis, Inc., San Antonio, TX), an
alternating cationic-aromatic peptide, are selective mitochondrial ROS
inhibitors which significantly improved post-reperfused cardiac function
compared to untreated I/R controls in this study (p<0.05). MitoQ elicits
antioxidant effects through the recycling of ubiquinone to ubiquinol, whereas
SS-31 utilizes an antioxidant dimethyltyrosine residue. Improvement in postreperfused cardiac function by MitoQ or SS-31 was associated with a
significant decrease in myocardial tissue infarct size compared to untreated
I/R hearts (p<0.01). These results suggest mitochondrial-derived ROS are
important contributors to I/R injury, and MitoQ or SS-31 when administered at
reperfusion may potentially augment the benefits of angioplasty or
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thrombolytic treatment in the clinical setting for myocardial infarction, where
pretreatment may not be a practical option.
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INTRODUCTION
The Clinical Setting of Myocardial I/R
Ischemic heart disease is the leading cause of morbidity and mortality in
the industrialized world and also is the leading cause of mortality in the United
States, accounting for nearly 20% of all deaths in the United States(1-5). Acute
myocardial infarction can progress into persisting conditions of morbidity, such as
heart failure(5, 6). During myocardial ischemia the coronary blood flow is
interrupted, depriving cardiomyocytes of oxygen (O2), glucose, and fatty acids.
Ischemia lasting for 30 minutes or longer will result in irreversible cardiac
damage(7). Quickly restoring blood flow (i.e., reperfusion) following ischemia is
critical in salvaging heart tissue. Surgical interventions, such as coronary
angioplasty or emergency coronary artery bypass grafting, as well as
thrombolytic drug treatments can enable restoration of coronary blood flow to
reduce the amount of irreversible tissue damage that occurs in the myocardium
during periods of prolonged ischemia(5, 8). However, as coronary blood flow is
reestablished, ischemic damage is exacerbated by a burst of reactive oxygen
species (ROS) generated within seconds of reperfusion(8, 9). Increased
oxidative stress during reperfusion contributes to the death of cardiomyocytes
that were viable before reperfusion occurred(10, 11). It has been suggested that
up to 50% of myocardial infarct size is due to reperfusion injury occurring after
ischemia, and the prognosis for patients surviving an acute myocardial infarction
is dependent on infarct size(5, 10). Clinical treatment of I/R injury remains a
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challenge as no approved pharmaceutical agents effectively limit I/R-induced
damage(4, 12).
The Need for Preclinical Investigation of Myocardial I/R
Jennings et al. first described the concept of myocardial I/R injury in 1960
using a canine I/R model, which resulted in cell swelling, myofibril contracture,
sarcolemma disruption, and calcium phosphate accumulation within
mitochondria(13). Treatment of myocardial I/R injury remains to be a challenge
because reperfusion itself is associated with ventricular arrhythmias, stunning
(i.e., contractile dysfunction of viable cells), and coronary vascular dysfunction(8,
10). Identifying the specific mechanisms by which myocardial I/R injury occurs
will allow for the development of efficient treatment strategies to reduce I/R injury
in myocardial infarction or heart transplantation patients and further prevent
ischemic heart failure. Effective cardioprotective treatment should reduce both
the amount of tissue infarction and viable cell dysfunction.
Implications of Mitochondria in Myocardial I/R
Ischemia has a direct effect on adenosine triphosphate (ATP) production.
As previously mentioned, ischemia prevents cardiomyocytes from receiving O2,
glucose, and fatty acids and also reduces the amount of adenine nucleotides and
cytochrome c available in mitochondria. Since mitochondria consume 85 to 90%
of the O2 in a cell to synthesize ATP from adenosine diphosphate (ADP) and
inorganic phosphate (Pi) during oxidative phosphorylation, the function of
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mitochondria is quickly disrupted by ischemia. Under normal conditions,
mitochondria produce over 90% of cellular energy in the form of ATP. Ischemic
conditions disrupt ATP production, leading to an overproduction of ROS at
reperfusion with the reestablishment of O2 supplied by coronary blood vessels.
Mitochondria are implicated in I/R as a major source of ROS(14-20). Excess
ROS leads to mitochondrial and cardiac contractile dysfunction, which can result
in cell damage and additional tissue death, contributing to I/R injury.
Mitochondria, Both a Source and a Target for ROS
Mitochondria are extremely susceptible to oxidative damage since a large
amount of ROS is generated within the mitochondria during I/R(14-18, 20). An
excess of ROS leads to mitochondrial dysfunction, which is an important factor in
the development of cardiac hypertrophy, contractile dysfunction, and subsequent
heart failure(1, 6, 21). This sequence of events could lead to a decreased ability
to recover from myocardial I/R and reduce the quality of life in patients following
myocardial I/R. In dysfunctional myocardium, there is a significant increase in
ROS production(1, 21, 22). Increased ROS production in dysfunctional
mitochondria induces further ROS production resulting in a feed forward-loop of
ROS elevation(14, 18). Dysfunctional mitochondria are associated with increased
ROS production and oxidative mitochondrial DNA damage due to their inability to
produce energy through the electron transport chain (ETC) complexes(6, 12, 21).
Since mitochondrial DNA is situated closer to the primary site of ROS generation
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and lacks both protective histones and efficient DNA repair mechanisms, it can
easily become mutated and potentially lead to cardiomyopathy(14, 18, 23, 24).
Sequence of ROS-Mediated I/R Damage:
The Mitochondrial Respiratory Chain Releases ROS
Oxidative phosphorylation is inactivated by ischemia, which results in an
accumulation of phosphate, fatty acids, lactic acid, and cellular calcium while
decreasing cellular pH and the amount of adenine nucleotides and cytochrome c
available in the mitochondria(10, 12, 25, 26). The rapid restoration of the
decreased pH upon reperfusion, possibly involving the opening of the
mitochondrial permeability transition pore complex (MPTP), is a contributing
factor to I/R injury. Reoxygenation with an acidic buffer inhibits opening of the
MPTP(10, 27). At the time of reperfusion, a burst of ROS including superoxide
(SO), hydrogen peroxide (H2O2), and peroxynitrite are generated by the
interaction of O2 with the damaged mitochondrial respiratory chain, primarily
through the uncoupling of complexes I and III(12, 28, 29). It is suggested that a
large portion of ROS in the I/R heart is a result of the uncoupling of complexes I
and III in the mitochondrial ETC(28). Under physiological conditions O2 is the
final electron acceptor, accepting four electrons from complex IV, and is used to
produce water (H2O), a by-product of respiration(14, 18)(Figure 1).
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Figure 1. Electron transport
chain (ETC) function in
physiological conditions.
Maintanence of the
electrochemical gradient of
the mitochondrial
membranes by the ETC is
essential for ATP production.
In these conditions, oxygen
(O2) accepts four electrons
from complex IV. Adapted
from Szeto 2006.

However, in dysfunctional mitochondria, electrons leaking from complexes I and
III are accepted by O2 to generate SO, a form of ROS(14, 18, 30)(Figure 2).
Figure 2. Electron transport
chain (ETC) function at
reperfusion. Oxygen (O2)
generates superoxide (O2-) by
accepting electrons leaking from
complexes I and III. Even though
O2- cannot diffuse across
membranes, O2- is generated in
both the intermembrane space
and within the matrix by this
mechanism. Forms of superoxide
dismutase can quickly convert
O2- to hydrogen peroxide (H2O2),
which is more stable and able to
diffuse into the cytosol. Adapted
from Szeto 2006 and modified.

Excessive amounts of ROS produced during myocardial I/R overwhelm the
physiological antioxidant mechanisms of glutathione, glutathione peroxidase,
thioredoxin, glutaredoxina-tocopherol, ubiquinol, ascorbic acid, superoxide
dismutase, and catalase(14, 18, 21, 26). The release of excess ROS damages
cells directly. As a signaling molecule, ROS can activate hypertrophy and
apoptosis pathways(21, 31-33). ROS directly damages nucleic acids, proteins,
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and lipids, consequently disrupting membrane integrity and cell function as a
result(14, 18, 21, 26, 30). SO can quickly be converted into H2O2, which is more
stable, has a longer half-life, and can diffuse across the mitochondrial
membranes into the cytosol(14, 32, 34). Conversion of H2O2 into hydroxyl
radicals or carbonate anions, which are both highly reactive forms of ROS, can
further promote oxidative stress(14). Adult rat cardiomyocytes treated with H2O2
showed that H2O2 concentration-dependently activates four kinase signaling
pathways (i.e., ERK1/2, p38 kinase, JNK, and Akt) involved in the regulation of
cardiomyocyte hypertrophy and/or apoptosis. Lower H2O2 concentrations
resulted in hypertrophy, while higher H2O2 concentrations induced apoptosis(31,
35, 36). Varying levels of oxidative stress induced in neonatal rat ventricular
myocytes also showed the same concentration-dependent effect of ROS on
cardiac hypertrophy and apoptosis(32, 37-40). Nitric oxide (NO) can interact with
SO to form peroxynitrite, a highly reactive form of ROS(30, 41). Peroxynitrite can
rapidly modify proteins, DNA, and membranes to cause oxidative damage(10,
21, 30, 42) and irreversibly inhibit cellular respiration(43).
Sequence of ROS-Mediated I/R Damage:
NADPH Oxidase, Another Important ROS Source
Another source of ROS that originates in the mitochondria of
cardiomyocytes and endothelial cells is nicotinamide adenine dinucleotide
phosphate oxidase (Nox)(10, 22, 44-48). Nox4, for example, is primarily localized
in mitochondria and exhibits increased ROS producing activity in dysfunctional
cardiomyocytes(22, 44-48). Genetic deletion of p47phox, the cytosolic component
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of Nox, has confirmed the implication of Nox in ROS-induced cardiac dysfunction
in a mouse myocardial infarction model. Analysis 30 days following myocardial
infarction showed that there was a reduction in left ventricular remodeling,
dysfunction, and dilation which paralleled the decrease in cardiomyocyte
apoptosis, hypertrophy, and intersititial fibrosis at the same time point. These
results also suggest that Nox may be involved in the development of heart failure
following myocardial infarction(6, 28, 48). However, it has been suggested that
Nox4, which is primarily localized in mitochondria, does not require p47phox,
p67phox, or Rac for activation but is dependent on SO levels for its expression.
At both cardiac cellular and tissue levels, the overexpression of Nox4 has been
shown to increase SO generation in mitochondria and contribute to cardiac
dysfunction, fibrosis, apoptosis, and mitochondrial dysfunction(49).
Sequence of ROS-Mediated I/R Damage:
ROS-induced eNOS Uncoupling
The production of ROS during reperfusion from mitochondria and Nox can
stimulate further increases in ROS formation as a feed-forward loop. ROS from
these sources may oxidize tetrahydrobiopterin (BH4) to dihydrobiopterin (BH2)
and consequently promote eNOS uncoupling, which leads to additional ROS
production(29, 50). When using BH2 as a co-factor, endothelial nitric oxide
synthase (eNOS) is considered uncoupled and produces SO instead of NO. The
release of SO from uncoupled eNOS causes oxidative damage and increases
production of other forms of ROS(51). A schematic diagram of the implications of
uncoupled eNOS in continuing the feed-forward loop of excessive ROS
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production in I/R is shown in Figure 3. This diagram focuses on protein kinase C
(PKC)-mediated ROS generation in I/R as an example, though other pathways
contributing to the feed-forward loop of ROS overproduction in I/R exist.

Figure 3. Schematic diagram of protein kinase C (PKC)-mediated ROS overproduction
in ischemia/reperfusion (I/R). The insult caused by I/R stimulates the release of
cytokines, which activate cytokine receptors. These cytokine receptors in turn generate
diacylglycerol (DAG), a second messenger signaling lipid which activates PKC. PKC
phosphorylates p47phox, an essential component in NADPH oxidase (Nox) activity, to
activate Nox, resulting in SO (O2-) release. Phosphorylation by PKC can also directly
promote O2- release from mitochondria and uncoupled eNOS. All of these sources of
excess O2- contribute to the oxidation of BH4 to BH2, which promotes further eNOS
uncoupling, resulting in a feed-forward loop of ROS overproduction during I/R. Adapted
and modified from Schmidt and Alp 2007.

It has previously been shown that eNOS uncoupling is a major source of
ROS in a hind limb I/R model and contributes to post-reperfused cardiac
contractile dysfunction in myocardial I/R(52). The uncoupling of eNOS can
quickly cause endothelial dysfunction within the first 5-10 min of reperfusion(52,
53). Hemodynamic stress is also known to lead to eNOS uncoupling. However,
supplementation with BH4 in mice with heart disease following pressure overload
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prevents eNOS uncoupling and reduces left ventricular hypertrophy, cardiac
dysfunction, and fibrosis (54). Folic acid also restores reduced BH4 production,
which increases coupled eNOS activity to protect the heart. Folic acid preserves
cardiac function in I/R rats, suggesting that there is a cardioprotective effect in
decreasing ROS production by increasing available BH4 to increase coupled
eNOS activity in I/R(55). Coupled eNOS produces NO.
Once NO is released it acts as a diffusable signaling molecule and
regulates blood pressure by increasing the production of cyclic guanosine
monophospate (cGMP) to relax smooth muscle(1). Previous studies have shown
that the pathway between eNOS, NO, and cGMP is an essential activator of
mitochondrial biogenesis(56, 57). Mitochondrial biogenesis increases energy
production and has a cardioprotective function in studies using rats, dogs, and
humans(58-62). NO is able to improve coronary blood flow, inhibit accumulation
of neutrophils, and inactivate SO radicals(10, 43, 63). The importance of these
effects of NO were demonstrated by systemically inhibiting NO synthesis in vivo,
resulting in peripheral vasoconstriction and hypertension, which induce
cardiovascular reflexes that change preload, afterload, and heart rate(43, 64, 65).
Additionally, it has been shown that NO regulates cellular respiration in the
myocardium by increasing the efficiency of O2 consumption in oxidative
phosphorylation. Inhibiting NO sythesis at all levels of cardiac contractile
performance significantly increased O2 consumption with no effect on the rate of
ATP synthesis or amount of ATP produced, suggesting that the effect of
inhibition of NO synthesis is unrelated to contractile performance. It has therefore
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been suggested that endogenous NO enhances the coupling of O2 consumption
to both ATP synthesis and cardiac performance(43). Despite its cardioprotective
effects, NO is also known to reversibly bind to cytochrome c to inhibit energy
production in the mitochondria and produce ROS and reactive nitrogen species
by displacing O2(66). NO can react with SO to generate peroxynitrite, a highly
reactive form of ROS(30, 42). NO is also able to induce apoptosis by activating
the opening of the MPTP(41). It has been demonstrated that at pathological
concentrations, NO activity switches from an anti-apoptotic effect to a proapoptotic effect(67, 68) Endothelial dysfunction is a key event to induce
leukocyte mediated inflammation leading to contractile dysfunction in the
myocardium(52, 53). This sequence of events contributes to I/R injury. However,
initiating sources of ROS that induce eNOS uncoupling are not well defined.
Investigating the initiating sources of ROS and ways to inhibit excess ROS
production in I/R is therefore of great significance.
Sequence of ROS-Mediated I/R Damage:
Lipid Peroxidation and Mitochondrial Permeability
As mentioned before, excess release of ROS leads to an increased
production of ROS. Lipid peroxidation can occur as a result of ROS release
during I/R and cause membrane damage, such as loss of membrane potential.
Lipid peroxidation can damage the sarcolemmal membrane and cause an
increase of intracellular calcium that overwhelms the physiological calcium
regulation mechanisms(10-12, 26). Excessive increases in intracellular calcium
leads to cardiac hypertrophy, fibrosis, opening of the MPTP, contractile
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dysfunction, cell death, and potentially heart failure(10, 11, 69). The opening of
the MPTP induces cell death by the irreversible loss of the mitochondrial
electrochemical membrane, causing mitochondrial swelling and rupture.
Cytochrome c release from the MPTP into the cytosol inhibits electron transport
and activates caspase mediated apoptosis cascades(12, 69, 70). Linoleic and
arachidonic acid, for example, are unsaturated fatty acids that create 4hydroxynonenal (HNE) as a by-product of their peroxidation. HNE can create
protein adducts and cause additional lipid peroxidation. HNE also induces
formation of mitochondrial membrane permeabilization (MMP) and subsequent
apoptosis. NO, peroxynitrite, and HNE can each independently cause lipid
peroxidation and MMP. It is suggested that this effect is mediated by MPTP since
the opening of the pore by this mechanism is inhibited by cyclosporin A, a direct
inhibiter of the MPTP(71). Cyclosporin A binds to cyclophilin D and detaches
cyclophilin D from the inner mitochondrial membrane(72) (Figure 4). The MPTP
is a channel made up of proteins that form a complex to span the inner and outer
mitochondrial membranes. The adenine nucleotide translocator, cyclophilin D,
and the voltage-dependent anion channel are the key functional MPTP
constituents(18, 72)(Figure 4).
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Figure 4. The mitochondrial
transition pore (MPTP) spans the
outer and inner mitochondrial
membranes. The peripheral
benzodiazepine receptor (IBP),
hexokinase (HK), adenine
nucleotide translocase (ANT),
creatine kinase (CK, in muscle
mitochondria) and cyclophilin D
(CpD) are the basic subunits of
the MPTP. When cyclosporin A
(CsA) binds (⊕) to CpD, CpD is
unable to associate with the
MPTP, preventing the MPTP
from opening. Adapted and
modified from Szewczyk and
Wojtzak 2002.

Although the mechanism by which NO, peroxynitrite, and HNE initiate MMP has
not been clearly defined, the adenine nucleotide translocator component of the
MPTP responds to these forms of ROS by opening the MPTP to increase MMP.
MMP can affect both the outer and inner mitochondrial membranes
simultaneously, or each individually. The opening of the MPTP uncouples
oxidative phosphorylation, reducing the amount of ATP available, and allows the
release of compounds normally sequestered by either or both of the
mitochondrial membranes(10, 42, 69). Both of these effects can result in cell
death. For example, prolonged MPTP opening can cause a loss of
electrochemical membrane potential and release cytochrome c, Smac/DIABLO,
and apoptosis-inducing factor (AIF) from the intermembrane space to activate
apoptosis pathways, including those mediated by caspase activity(26, 41)(Figure
5).
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Figure 5. The mitochondrial
transition pore (MPTP) in
apoptosis pathways. ROS,
DNA damage, and other
apoptosis-inducing signals
promote the binding of Bax, a
proapoptotic protein, with the
outer mitochondrial membrane
near the MPTP. Bax activity
promotes the opening of the
MPTP, which releases
cytochrome c and apoptosisinducing factor (AIF) into the
cytosol. Elevated calcium and
ROS can also directly stimulate
MPTP opening. The release of
cytochrome c and AIF into the
cytosol activates caspasemediated apoptosis pathways.
Adapted from Szewczyk and
Wojtzak 2002 and modified.

Mitochondria as a Potential Therapeutic Target in I/R
Although mitochondrial-targeted antioxidant pretreatment can effectively
limit I/R injury, pretreatment is not always possible in cases of myocardial
infarction(5, 15, 16, 73, 74). Therefore, evaluating the cardioprotective efficacy of
mitochondrial-targeted antioxidants when given at reperfusion is of high
significance. Previous studies have shown that selective mitochondrial
antioxidants administered before ischemia and at reperfusion can reduce heart,
liver, and kidney damage beginning immediately following ischemia, thus
suggesting that selective mitochondrial antioxidants can work quickly in
attenuating I/R injury(18, 30, 75). If these agents can work expeditiously and
effectively when administered at the time of coronary blood flow restoration,
mitochondrial-targeted antioxidants may be a practical option in the clinical
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setting in cases of myocardial infarction. Following myocardial I/R, treatments
that can attenuate endothelial and cardiac contractile dysfunction will limit tissue
damage and allow these patients to have a better quality of life.
Mitoquinone, a Mitochondrial-Targeted Antioxidant
Conventional antioxidants, such as coenzyme Q, vitamin E, and Nacetylcysteine, have limited efficacy in protecting mitochondria from oxidative
damage because they are not targeted selectively to the mitochondria, where
most I/R damage occurs(14-18, 26). Therefore, selectively targeting mitochondria
with antioxidants may be an effective strategy to attenuate release of
mitochondrial ROS (Figure 6).
Figure 6. Reduction of mitochondrial
reactive oxygen species (ROS) limits
excess cell death. Mitochondrial
ROS stimulate ROS production
outside mitochondria, increasing
oxidative stress and apoptosis
signaling cascade activation. ETC
complexes and Nox4 are major ROS
sources in dysfunctional
mitochondria. Specific mitochondrialtargeted antioxidants exert
cardioprotective effects. Adapted
from Bayeva et al. 2013 and
modified.

Attachment of an antioxidant to a lipophilic cation allows the antioxidant to
concentrate 100 to 1000-fold within mitochondria(14, 17, 76). Mitoquinone
(MitoQ, MW=579g/mol; the MitoQ referred to in this study was complexed with
cyclodextrin (MW=1135g/mol) to improve water solubility, total MW=1714g/mol),
a coenzyme Q analog, incorporates a lipophilic triphenylphosphonium (TPP)
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cation, which easily passes through phospholipid bilayers and is driven by the
large electrochemical mitochondrial membrane potential (150-180 mV), to
concentrate MitoQ specifically within the mitochondria at a several hundred-fold
concentration(16-18, 76). The TPP cation is covalently attached to an ubiquinol
antioxidant to scavenge ROS and prevent lipid peroxidation(1, 16, 17, 76, 77).
After entering the mitochondria, the respiratory chain reduces MitoQ to its active
ubiquinol form. A previous study has shown that accumulation of ubiquinol within
mitochondria is necessary for the efficacy of MitoQ in limiting myocardial I/R
injury since quinol by itself is unable to cross the mitochondrial membrane(16).
The oxidation of MitoQ into its quinone form scavenges ROS inside
mitochondria; complex II of the respiratory chain then recycles MitoQ back into its
active quinol form continuously after each time MitoQ completes antioxidant
activity(16, 17, 78). Another aspect of MitoQ that could make it an attractive
therapeutic tool is that no significant adverse effects have been reported after
long-term administration. MitoQ does not act as a pro-oxidant in wild-type mice in
vivo(17). No significant adverse effects were reported when MitoQ was
administered as an oral tablet to patients for up to a year, however there was
mild nausea and vomiting reported in the MitoQ treatment groups(76, 79). In one
study, administration of MitoQ (500 µM in drinking water) to mice for 20-28 weeks
allowed MitoQ to accumulate primarily in the liver and heart but also slightly in
the brain. Long term MitoQ administration did not increase mitochondrial
oxidative stress in vivo, suggesting that MitoQ does not have pro-oxidant effects
when administered over an extended period of time. Additionally, mitochondrial
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enzyme activity was not negatively affected. MitoQ seemed to reduce plasma
levels of triglyceride but did not alter glucose, insulin, free fatty acid, or
cholesterol levels in plasma. Additionally, these MitoQ treated mouse heart and
liver tissues did not have any significant differences in their gene expression
profile compared to untreated controls(17). In human studies where MitoQ was
administered orally as a daily dose for up to one year, no severe side effects
were reported(76, 79). Another aspect of TPP conjugated antioxidants is that
uptake is reversible; they can be rapidly cleared from any organ of the body once
administration is stopped(80).
SS-31, Also a Mitochondrial-Targeted Antioxidant
The SS-31 (Szeto-Schiller) peptide ((D-Arg)-Dmt-Lys-Phe-Amide,
MW=639 g/mol, Genemed Synthesis, Inc., San Antonio, TX) is also of interest in
further understanding the role of mitochondrial derived ROS and efficacy of
inhibiting mitochondrial ROS production in myocardial I/R. SS-31 is a cellpermeable peptide, specifically targeted to inner mitochondrial membranes
based on its alternating aromatic residues and basic amino acid sequence, with
an antioxidant dimethyltyrosine moiety (Dmt)(14, 26). Tyrosine scavenges ROS
to form unreactive compounds, attributing the ability of SS-31 to scavenge ROS
to the Dmt amino acid residue, which has been found to be more effective than
tyrosine(18, 81, 82). The backbones of most peptides have a tendency to form
hydrogen bonds with water, making these peptides not cell-permeable. However,
the alternating aromatic-cationic motif of SS-31 allows it to rapidly diffuse through
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cell membranes(18). Unlike TPP-conjugated antioxidants, SS-31 does not rely on
the electrochemical mitochondrial membrane potential to selectively accumulate
10,000-fold inside mitochondria(14, 18). In dysfunctional mitochondria, the
electrochemical membrane potential may be disrupted(18, 73). Therefore, the
ability to target an antioxidant selectively to mitochondria independent of
membrane potential may prove useful in I/R. Additionally, high doses of lipophilic
cation attached antioxidants may depolarize the mitochondrial membrane
potential, but SS-31 at concentrations as high as 1 mM did not depolarize the
mitochondrial membrane potential(14, 18, 26). SS-31 can cross plasma
membranes in both directions in an energy-independent manner(14, 26, 83). In
liver and brain mitochondria, SS-31 reached its maximum intracellular
concentration within 2 min of incubation(26). SS-31 achieved steady state by 30
minutes of incubation with neuronal cell lines(26). SS peptides have relatively
long elimination half-lives and are also small, water soluble, stable and resistant
to peptidase degradation(14, 26). When SS-31 was incubated in mouse, rat, dog,
monkey and human plasma at 37 oC for 1 hour there was little degradation. SS31 was most stable in human plasma, with a half-life of about 30 hours, and was
classified as a low clearance compound in human liver microsomes(12, 84).
Previous studies have shown that in ex vivo and in vivo I/R models, SS peptides
scavenge H2O2, hydroxyl radicals, and peroxynitrite while also inhibiting lipid
peroxidation. Consequently, there is less cytochrome c release and subsequent
oxidant-induced cell death because the opening of the MPTP is inhibited(12, 14,
18, 26, 73, 85). Since SS-31 reduced infarct size and tissue dysfunction in I/R
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models as a pretreatment, it is possible that SS-31 would have a similar effect
when administered at reperfusion(86). One limitation of previous studies is that
they did not measure both cardiac function and infarct size in the same animals
that were administered SS-31 exclusively at the time of reperfusion.
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HYPOTHESIS
It has previously been determined that the formation of ROS within the
mitochondria under I/R conditions is a major contributor to I/R injury(14-16). It is
hypothesized that antioxidants specifically targeted to the mitochondria to
attenuate ROS formation will reduce I/R injury by limiting cardiac contractile
dysfunction and cardiac tissue damage. MitoQ, a coenzyme Q derivative, and
SS-31, an alternating cationic-aromatic peptide, are selective mitochondrial ROS
inhibitors. MitoQ incorporates a lipophilic TPP cation covalently attached to a
ubiquinol antioxidant, whereas SS-31 is a cell-permeable peptide with an
antioxidant dimethyltyrosine residue specifically targeted to the inner
mitochondrial membrane based on its alternating cationic aromatic residue
sequence(15, 16, 87). It is expected that the myocardial I/R rat hearts treated
with MitoQ or SS-31, given at reperfusion, will have greater preserved cardiac
contractile function and smaller infarct size following myocardial I/R in
comparison to the untreated I/R rat hearts.
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METHODS
Isolated Rat Heart Preparation
Male Sprague-Dawley rats (275-325 g, Charles River, Springfield, MA)
were anesthetized intraperitoneally (i.p.) with pentobarbital sodium (60 mg/kg);
the injection also contained sodium heparin (1,000 U). Each heart was rapidly
excised and subjected to retrograde perfusion via the aorta with a modified
Krebs-Henseleit buffer (in mmol/L: 17.0 dextrose, 120.0 NaCl, 25.0 NaHCO3, 2.5
CaCl2, 0.5 EDTA, 5.9 KCl and 1.2 MgCl2). The perfusate was maintained at
37 oC, kept at 80 mmHg constant pressure, aerated with 95% O2-5% CO2 and
equilibrated at a pH of 7.35-7.45(88, 89).
The aorta of the isolated rat heart was cannulated onto a perfusion needle
and immersed in a water-jacketed reservoir containing 160 mL of modified
Krebs-Henseleit buffer (Figure 7).
Figure 7. The isolated perfused rat heart was
cannulated via the aorta with a perfusion needle while
immersed in a water-jacketed reservoir containing
160 mL of modified Krebs-Henseleit buffer. Also
shown in this picture is the pressure transducer
inserted into the left ventricular cavity to monitor
cardiac function parameters.

A flowmeter (T106, Transonic Systems, Inc.,
Ithaca, NY) was inserted into the perfusion line to
monitor coronary flow. Left ventricular endsystolic pressure (LVESP), left ventricular enddiastolic pressure (LVEDP), heart rate, and the peak rates of rise and fall in the
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first derivative of left ventricular pressure (dP/dtmax and dP/dtmin, respectively)
were monitored using a pressure transducer (SPR-524, Millar Instruments, Inc.,
Houston, TX) positioned in the left ventricular cavity and recorded using a
Powerlab Station acquisition system (ADInstruments, Grand Junction, CO). Left
ventricular developed pressure (LVDP) was calculated by subtracting the LVEDP
from the LVESP. Insertion of the pressure transducer catheter into the left
ventricle allowed Krebs’ buffer to fill the left ventricle and establish preload
volume. During the baseline period, the preload of the hearts of all study groups
were be similar due to the limited weight range (275-325 g) of the animals as
seen in previous studies(89-91). The initial baseline LVEDP was between 4-9
mmHg for all hearts in each study group. Coronary flow, LVESP, LVEDP, heart
rate, dP/dtmax, and dP/dtmin were measured every 5 min for 15 min to ensure that
stable baseline measurements were obtained. Figure 8 illustrates a schematic
diagram of the I/R protocol in the isolated perfused rat heart.
baseline
ischemia
stabilization

reperfusion

15 min
↑
heart
connected to
I/R apparatus

45 min
↑
autologous plasma ± MitoQ or SS-31
infusion

30 min
↑
flow of modified
Krebs-Henseleit
buffer reduced to 0

TTC
staining

Figure 8. Myocardial I/R protocol. A 30 min perfusion period replaced ischemia in sham
groups. At the beginning of the 45 min reperfusion period, 5 mL of autologous plasma ±
MitoQ or SS-31 was infused 1 mL/min for 5 min.

Once a stable baseline was established, ischemia was induced for 30 min
by quickly reducing the flow of Krebs’ buffer to zero. One of the three side arms
in the perfusion line proximal to the heart inflow cannula was used for the
infusion of 5 mL of autologous plasma (control hearts) or autologous plasma

22
containing MitoQ (1, 10, 20 μM) or SS-31 (25, 50, 100 μM). After 30 min of
ischemia, the flow of Krebs’ buffer was restored simultaneously with an infusion
of either 5 mL of plasma (control I/R) or 5 mL of plasma containing MitoQ or SS31 at a rate of 1 mL/min for 5 min. Sham hearts were not subjected to ischemia
and were given the 5 mL infusion of plasma at a rate of 1 mL/min for 5 min
following 30 minutes of continuous perfusion in lieu of ischemia. Beginning at the
infusion of plasma, cardiac function parameters were recorded every 5 min for 45
min.
At the end of the experimental protocol, the right and left ventricles were
separated from each heart. Three sections of the left ventricle were used for
2,3,5- triphenyltetrazolium chloride (TTC) staining.
Groups of Isolated Perfused Hearts
The 9 groups of isolated perfused rat hearts used in the study are shown
in Table 1. Two types of control groups were used in the study based on
previously established myocardial I/R models. Sham hearts were continuously
perfused with the modified Krebs-Henseleit buffer for a 30 min period in lieu of
the 30 min ischemia period and infused with 5 mL of plasma (1 mL/min)
immediately following the 30 min perfusion period (i.e., the same time point that
all I/R hearts would be given 5 mL of plasma). This group was utilized to show
that cardiac function (i.e., LVDP, dP/dtmax, dP/dtmin, coronary flow,, and heart
rate) is maintained with no significant changes over a 90 min isolated perfused
heart protocol, suggesting that any damage or cadiac dysfunction is due to injury
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associated with ischemia and reperfusion. Control I/R hearts were subjected to a
30 min period of ischemia followed by 45 min of reperfusion including an infusion
of 5 mL of plasma (1 mL/min) in the first 5 min of reperfusion immediately
following ischemia. This group was used to show the compromised
postreperfused heart function after 30 min ischemia and 45 min reperfusion in
the absence of any drugs compared to the baseline measurements of cardiac
function. The drug treated I/R groups consist of I/R + MitoQ and I/R + SS-31 as
shown in Table 1.
Table 1. Isolated Perfused Rat Heart Treatment Groups
Control I/R
MitoQ
1 μM
10 μM
20 μM
25 μM
Sham
n=6
I/R
n=14
n=6
n=7
n=6
n=6

SS-31
50 μM
n=6

100 μM
n=6

Isolation of Plasma
Blood was collected in 1 mL of citrate phosphate dextrose buffer (Sigma
Chemical Co., St. Louis, MO) from the abdominal aorta of the same rat from
which the heart was isolated for each myocardial I/R experiment to simulate in
vivo conditions. The blood was centrifuged at 10,000 x g for 10 min at 4 °C. The
plasma was decanted from the blood, and 5 mL of the plasma collected from
each rat was used for its corresponding isolated perfused heart during the
infusion period at the beginning of reperfusion in all myocardial I/R groups.
TTC Staining
Once the 45 min reperfusion period was complete, the right ventricle was
separated from the left ventricle and placed in liquid nitrogen. The apex and two
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middle sections were isolated from the base of the left ventricle, and the base of
the left ventricle was placed in liquid nitrogen. The apex and two middle sections
were each placed in 1 mL of TTC for 15 min to visualize infarcted tissue areas.
TTC is a salt that can be reduced by dehydrogenases to triphenylformazan, a fat
soluble, light-sensitive compound which stains viable tissue bright red. Areas
deficient in dehydrogenase activity remain the pale white color of the TTC salt.
Previous studies have shown that the differentiation between viable and infarcted
tissue by TTC staining correlates with loss of dehydrogenase activity and is
therefore a reliable tool to measure infarct size(92-94). The weight ratio of
infarcted cardiac tissue to the total area of tissue at risk was calculated and
statistically analyzed.
Statistical Analysis
All data in the text and figures were presented as means ± SEM. The
cardiac function and TTC staining data were analyzed by ANOVA using post hoc
analysis with the Student-Newman-Keuls test. Probability values of <0.05 were
considered to be statistically significant.
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RESULTS
I/R + MitoQ (1 μM, 10 μM, 20 μM)
Cardiac Function
Sham hearts, which were not subjected to ischemia, are shown in all
cardiac function graphs as reference points to illustrate the impact of I/R on
cardiac function. Table 2 expresses the percent recovery, a comparison of the
final to initial values, and Figures 9, 10, and 11 show the initial and final values of
LVDP, dP/dtmax, and dP/dtmin from each experimental group, respectively.
Table 2. Infarct Size (%) and LVDP, dP/dtmax, and dP/dtmax Percent Recovery
Control I/R
MitoQ
SS-31
1 μM
10 μM
20 μM
25 μM
50 μM
100 μM
45.0±2.1
53.9±6.3
26.7±3.2**
23.3±2.1**
25.2±3.8**
18.9±2.0**
20.6±1.9**
Infarct
Size
47.6±3.0
58.9±9.2
76.7±4.0*
69.5±7.8*
47.3±5.9
80.6±3.4**
62.1±6.4
LVDP
dP/dtmax 37.7±3.0 40.9±7.4 62.0±3.3* 55.2±5.4* 42.6±3.1 70.5±5.8** 49.0±2.6
48.7±1.3
59.4±8.8
72.1±8.2
63.5±10.4
43.1±5.2
81.4±4.1*
61.7±7.9
dP/dtmin
All data were analyzed using ANOVA with the Student Newman Keuls test (*p<0.05,
**p<0.01 compared to control I/R)

There was no statistically significant difference initially between the
baseline values between any of the experimental groups. Additionally, there was
no statistically significant difference between the initial and final values of LVDP,
dP/dtmax, or dP/dtmin in the sham hearts. The sham hearts showed that there is
not a significant decrease in cardiac function due to the experimental protocol in
lieu of ischemia. In contrast, cardiac function of the control I/R hearts was
significantly compromised by 45 min postreperfusion compared to baseline
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cardiac function (P<0.01). At the end of each experiment, control I/R hearts
recovered to 47.6 ± 3.0 % of initial LVDP, 37.7 ± 3.0 % of initial dP/dtmax, and
48.7 ± 1.3 % dP/dtmin (Table 2, Figs. 9-11). I/R hearts treated with MitoQ (10, 20
μM) significantly recovered in LVDP and dP/dtmax (P<0.05 compared to control
I/R; Table 2, Figs. 9 and 10); whereas lower dose (1 µM) MitoQ was not
statistically different from the I/R control (Table 2, Figs. 9 and 10). Interestingly,
even though MitoQ (10, 20 μM) was able to improve postreperfused dP/dtmax,
there was not a significant difference in the postreperfused dP/dtmin between the
MitoQ (10, 20 μM) treated I/R hearts and untreated I/R hearts (Table 2, Fig. 11).
Overall, these results suggest that the infusion of MitoQ (10, 20 μM) at
reperfusion improves postreperfused cardiac contractile function compared to I/R
control hearts (P<0.05).
Figure 9. Initial (before
ischemia) and final (at 45
min reperfusion)
measurements from
isolated perfused rat
hearts of left ventricular
developed pressure
(LVDP), expressed in
mmHg. (*P<0.05
compared to control). All
values are expressed as
mean ± SEM. The number
of hearts in each
experimental group is
shown in the box at the
base of each bar.
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Figure 10. Initial (before
ischemia) and final (at 45
min reperfusion)
measurements from
isolated perfused rat
hearts of the peak rate of
rise in the first derivative of
left ventricular systolic
pressure (dP/dtmax),
expressed in mmHg/s.
(*P<0.05 compared to
control). All values are
expressed as mean ±
SEM. The number of
hearts in each
experimental group is
shown in the box at the
base of each bar.

Figure 11. Initial (before
ischemia) and final (at
45 min reperfusion)
measurements from
isolated perfused rat
hearts of the minimal
rate of left ventricular
systolic pressure in the
first derivative (dP/dtmin),
expressed in mmHg/s.
(*P<0.05 compared to
control). All values are
expressed as mean ±
SEM. The number of
hearts in each
experimental group is
shown in the box at the
base of each bar.

Moreover, the time courses of LVDP, dP/dtmax, and dP/dtmin show that the
I/R control group exhibited sustained contractile dysfunction throughout the 45
min period of reperfusion following ischemia compared to the sham hearts that
did not experience ischemia (P<0.01). However, the I/R hearts treated with 10
μM MitoQ showed significantly recovered LVDP by the 20 min time point and
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significantly recovered dP/dtmax by the 30 min time point, suggesting that cardiac
contractile function can recover more quickly after an infusion of MitoQ (10 μM)
and sustain better contractile function by 45 min of reperfusion compared to
untreated I/R controls (Figs. 12 and 13, both P<0.05). Additionally, I/R hearts
treated with 20 μM MitoQ showed significant improvement in LVDP and dP/dtmax
by 40 min reperfusion compared to untreated I/R controls (Figs. 12 and 13, both
P<0.05). However, MitoQ (10, 20 μM) was not able to significantly restore
dP/dtmin compared to untreated I/R control hearts (Fig. 14). The I/R hearts treated
with a 1 μM dose of MitoQ did not show any significant changes in LVDP,
dP/dtmax, or dP/dtmin throughout the I/R timecourse (Figs. 12-14).

Figure 12. Time course of measurements of left ventricular developed pressure (LVDP)
expressed in mmHg from initial baseline period (before ischemia) to the final recording
time point (at 45 min reperfusion) from isolated perfused rat hearts (*P<0.05, **P<0.01
compared to control I/R; †P<0.05 compared to MitoQ 20 µM). All values are expressed
as mean ± SEM.
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Figure 13. Time course of measurements of the peak rate of rise in the first derivative of
left ventricular systolic pressure (dP/dtmax) expressed in mmHg/s from initial baseline
period (before ischemia) to the final recording time point (at 45 min reperfusion) from
isolated perfused rat hearts. (*P<0.05, **P<0.01 compared to control I/R;
#
P<0.05;†P<0.05 compared to MitoQ 20 µM). All values are expressed as mean ± SEM.

Figure 14. Time course of measurements of the minimal rate of left ventricular systolic
pressure in the first derivative (dP/dtmin) expressed in mmHg/s from initial baseline period
(before ischemia) to the final recording time point (at 45 min reperfusion) from isolated
perfused rat hearts. All values are expressed as mean ± SEM.
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I/R + SS-31 (25 μM, 50 μM, 100 μM)
Cardiac Function
Figures 15, 16, and 17 show the initial and final values of LVDP, dP/dtmax,
and dP/dtmin from each experimental group, respectively. There was no
statistically significant difference initially between the baseline values between
any of the experimental groups. I/R hearts treated with SS-31 50 μM significantly
recovered in LVDP, dP/dtmax, and dP/dtmin compared to untreated control I/R
(P<0.01 compared to untreated control I/R, Table 2, Figs. 15-17); whereas SS-31
(25, 100 µM) treatment did not show statistical difference from the untreated I/R
control (Table 2, Figs. 15-17).
Figure 15. Initial (before
ischemia) and final (at 45 min
reperfusion) measurements
from isolated perfused rat
hearts of left ventricular
developed pressure (LVDP),
expressed in mmHg.
(**P<0.01 compared to
control I/R). All values are
expressed as mean ± SEM.
The number of hearts in each
experimental group is shown
in the box at the base of each
bar.

31
Figure 16. Initial (before
ischemia) and final (at 45
min reperfusion)
measurements from isolated
perfused rat hearts of the
peak rate of rise in the first
derivative of left ventricular
systolic pressure (dP/dtmax),
expressed in mmHg/s.
(**P<0.01 compared to
control I/R). All values are
expressed as mean ± SEM.
The number of hearts in
each experimental group is
shown in the box at the base
of each bar.

Figure 17. Initial (before
ischemia) and final (at 45
min reperfusion)
measurements from
isolated perfused rat
hearts of the minimal rate
of left ventricular systolic
pressure in the first
derivative (dP/dtmin)
expressed in mmHg/s.
(**P<0.01 compared to
control I/R). All values
are expressed as mean ±
SEM. The number of
hearts in each
experimental group is
shown in the box at the
base of each bar.

Moreover, the time courses of LVDP, dP/dtmax, and dP/dtmin show that the
I/R control group exhibited sustained contractile dysfunction throughout the 45
min period of reperfusion following ischemia compared to the sham hearts that
did not experience ischemia (P<0.01). However, the I/R hearts treated with 50
μM SS-31 showed significantly recovered LVDP, dP/dtmax, and dP/dtmin by the 15
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min time point, suggesting that cardiac contractile function can recover more
quickly after an infusion of SS-31 (50 μM) and sustain better contractile function
by 45 min of reperfusion compared to untreated I/R controls (Figs. 18-20, all
P<0.01).

Figure 18. Time course of measurements of left ventricular developed pressure (LVDP)
expressed in mmHg from initial baseline period (before ischemia) to the final recording
time point (at 45 min reperfusion) from isolated perfused rat hearts. Infusion of SS-31 at
reperfusion attenuated cardiac contractile dysfunction by allowing LVDP to recover
closer to baseline values throughout the time course of the experiment (**P<0.01
compared to control I/R; #P<0.05, ##P<0.01 compared to SS-31 25 µM;†P<0.05
compared to SS-31 100 µM). All values are expressed as mean ± SEM.
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Figure 19. Time course of measurements of the peak rate of rise in the first derivative of
left ventricular systolic pressure (dP/dtmax) expressed in mmHg/s from initial baseline
period (before ischemia) to the final recording time point (at 45 min reperfusion) from
isolated perfused rat hearts. Infusion of SS-31 at reperfusion attenuated cardiac
contractile dysfunction by allowing dP/dtmax to recover closer to baseline values
throughout the time course of the experiment (**P<0.01 compared to control I/R;
#
P<0.05, ##P<0.01 compared to SS-31 25 µM;†P<0.05,††P<0.01 compared to SS-31 100
µM). All values are expressed as mean ± SEM.
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Figure 20. Time course of measurements of the minimal rate of left ventricular systolic
pressure in the first derivative (dP/dtmin) expressed in mmHg/s from initial baseline period
(before ischemia) to the final recording time point (at 45 min reperfusion) from isolated
perfused rat hearts. Infusion of SS-31 at reperfusion attenuated cardiac contractile
dysfunction by allowing dP/dtmin to recover closer to baseline values throughout the time
course of the experiment (*P<0.05, **P<0.01 compared to control I/R; #P<0.05, ##P<0.01
compared to SS-31 25 µM;†P<0.05 compared to SS-31 100 µM)All values are
expressed as mean ± SEM.

I/R + MitoQ (1 μM, 10 μM, 20 μM) and I/R + SS-31 (25 μM, 50 μM, 100 μM)
Infarct Size
Figure 21 illustrates cross sections of left ventricular tissue stained with
1% TTC to detect infarct size.

Figure 21. Representative cross sections of I/R left ventricles subjected to TTC staining.
Viable tissue stained red while the areas of infarction stained white.
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The weight ratio of cardiac tissue infarct to the total area at risk was calculated
and statistically analyzed. The I/R hearts treated with MitoQ (10 μM and 20 μM)
or SS-31 (25, 50, 100 μM) showed a significantly smaller infarct size compared to
untreated I/R controls (P<0.01 compared to control I/R; Table 2, Fig. 22). These
results suggest that the infusion of MitoQ or SS-31 at reperfusion significantly
reduces the amount of cardiac tissue death following I/R. However, the I/R hearts
treated with 1 μM MitoQ did not show a significant difference in infarct size
compared to untreated I/R hearts, suggesting that there is no cardioprotective
effect at this dose (Fig. 22).

Figure 22. Ratio of infarct size to total cardiac tissue at risk as determined by TTC
staining. Infusion of MitoQ (10, 20 μM) or SS-31 (25, 50, 100 μM) at reperfusion
attenuated cardiac tissue death compared to untreated I/R hearts (*P<0.05, **P<0.01).
All values are expressed as mean ± SEM.
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DISCUSSION
Summary of major findings
The results of this study suggest the infusion of MitoQ (10, 20 μM) at
reperfusion improves postreperfused cardiac contractile function compared to I/R
control hearts. The effect of MitoQ on cardiac function correlates with the infarct
size data, suggesting the effects of the infusion of MitoQ at reperfusion can range
from 1 to 20 μM. By contrast, all SS-31 treated I/R hearts showed a reduction in
infarct size compared to the untreated control I/R hearts, but only the 50 μM dose
of SS-31 elicited improvement in cardiac function within the 45 minute
reperfusion period. This result is consistent with a previous myocardial I/R study
in which a SS-31 analog (i.e., Bendavia) showed a reduction in infarct size but no
significant improvement in cardiac function(95). Kloner et al. suggest SS peptides
can reduce infarct size in I/R but may not improve post-reperfused cardiac
function because the myocardium may be reversibly stunned and require more
time to improve. Similarly, in this myocardial I/R study, SS-31 significantly
reduced infarct size compared to the untreated control I/R hearts, yet the 25 and
100 μM doses of SS-31 could not restore cardiac function within the 45 minute
reperfusion period as quickly as the 50 μM dose of SS-31. Since it has been
suggested that most I/R-induced damage occurs within the first 5 minutes of
reperfusion, it is important to discover agents that can work rapidly and
effectively to reduce the amount of I/R injury(8, 9).
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These results suggest that mitochondrial ROS may be a significant
contributor to myocardial I/R injury and are consistent with the hypothesis that
inhibiting the release and accumulation of excess mitochondrial ROS with MitoQ
or SS-31 attenuates myocardial I/R injury and subsequent cardiac contractile
dysfunction and tissue death.
The effects of MitoQ on cardiac contractile function and infarct size in I/R
The administration of MitoQ (10, 20 μM) at reperfusion significantly
restored postreperfused LVDP and dP/dtmax closer to baseline levels and
reduced infarct size in comparison to untreated I/R hearts. Although the 10 and
20 μM doses of MitoQ significantly restored LVDP and dP/dtmax (P<0.05), none of
the doses of MitoQ significantly restored postreperfused dP/dtmin in comparison to
I/R controls. This finding suggests that postreperfused MitoQ treated hearts
reach maximum contractility quickly but relax at a rate comparable to that of
postreperfused untreated I/R hearts. MitoQ (10, 20 μM) administered at
reperfusion was able to allow LVDP to recover more closely to baseline values
after 45 min reperfusion than untreated I/R hearts. Although there was no
significant difference in LVEDP between the experimental groups at the final time
point in these experiments, lower post-I/R LVEDP could possibly contribute to the
improved LVDP recovery in MitoQ-treated hearts. Although the I/R hearts treated
with 20 μM of MitoQ reached final contractile function measurements similar to
those of the I/R hearts treated with 10 μM, the time course of the I/R hearts
treated with 20 μM showed that these hearts did not significantly differ from
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untreated control I/R hearts in the 5-35 min period of reperfusion. In contrast, the
I/R hearts treated with 10 μM of MitoQ significantly improved in LVDP by the 15
min time point and in dP/dtmax by the 30 min time point. This delay in effect of the
20 μM dose of MitoQ could possibly be attributed to reversible dysfunction in
viable cells since these hearts significantly recovered LVDP and dP/dtmax by 45
min reperfusion and also had a significantly smaller infarct size compared to
untreated control I/R hearts. There was no statistical significance between MitoQ
(1, 10, 20 μM) and untreated I/R hearts in the heart rate, coronary flow, LVESP,
or LVEDP final values. While it would be expected that a decrease in infarct size
would correlate with an increase in coronary flow, such an effect was not evident
in this study(89, 95-97). In summary, postreperfused MitoQ-treated I/R hearts
display significantly restored cardiac contractile function and smaller infarct size
than untreated I/R hearts. These results suggest that mitochondrial ROS may be
a significant contributor to myocardial I/R injury, and inhibiting the release of
mitochondrial ROS with selective mitochondria-targeted antioxidants attenuates
myocardial I/R injury and subsequent cardiac contractile dysfunction.
These results are consistent with the findings of other studies in which
MitoQ attenuated tissue damage and dysfunction in I/R models. The Adlam et al.
2005 study reported that a pretreatment of MitoQ (500μM) in drinking water given
to rats for two weeks prior to I(30min)/R(60min) improved postreperfused cardiac
function in isolated rat hearts compared to I/R control hearts. Specifically, MitoQtreated rat hearts achieved a significantly improved recovery of postreperfused
LVDP in comparision to treatment with untargeted antioxidant compounds(16). A
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similar study using pretreatment with MitoQ (500 μM) in drinking water for 10
days prior to I(20min)/R(90min) in isolated perfused rat hearts showed an
improvement in LVDP by 20% compared to I/R control hearts(74). The response
to myocardial I/R of the MitoQ pretreated isolated perfused hearts in these
studies suggests that mitochondria-derived ROS is a source of oxidative stress
implicated in myocardial I/R injury.
The cardioprotective effects attributed to MitoQ were also investigated in
another study in which rats were treated with doxorubicin (DOX), a drug known to
induce cardiomyopathy, and MitoQ. These rats were treated for 12 weeks with
DOX, MitoQ, or DOX plus MitoQ. Two-dimensional echocardiography measured
the left ventricular function, which decreased in DOX-treated rats but was
preserved during MitoQ plus DOX treatment. In addition, cytochrome c oxidase
function was restored in DOX plus MitoQ (2 mg/kg) rats but diminished in DOXtreated rats(98). The dose of MitoQ administered in the DOX-treated rat study is
similar to the dose range used by our research group to show a reduction in rat
blood H2O2 levels when administered during reperfusion compared to untreated
I/R controls(99). In a hypertensive rat model of cardiovascular disease, MitoQ
reduced cardiac dysfunction, blood pressure, cardiac hypertrophy, and
endothelial dysfunction(100). Bovine aortic endothelial cells pretreated with
MitoQ (1 µM) and incubated with glucose/glucose oxidase, to induce caspase
activation, inhibited H2O2-induced apoptosis and lipid and protein peroxidation
while also preserving mitochondrial membrane potential(101). Although
pretreatment with MitoQ in these studies exhibited significant cardioprotective
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effects, administering MitoQ as a pretreatment may not be a practical option in
clinical occurrences of myocardial infarction. Therefore, administering MitoQ at
reperfusion may prove more useful. MitoQ has exhibited protective effects when
given during reperfusion following one hour ischemia in liver I/R and resulted in
reduced ALT and AST liver enzymes immediately following ischemia and
throughout a 24 hour reperfusion. Consequently, a smaller percentage of
damaged liver tissue was found in the MitoQ treatment group(30). The
concentration of MitoQ used in this liver I/R model was similar to the doses of
MitoQ used in our in vivo hind limb I/R and ex vivo myocardial I/R models, which
showed that MitoQ can reduce blood H2O2 levels and infarct size, respectively, in
I/R(99, 102). Antioxidants that are targeted specifically to mitochondria,
especially those that work rapidly and achieve efficacy when administered upon
reperfusion, may be useful clinically in reducing mitochondrial oxidative damage
following the reperfusion of ischemic tissue.
The effects of SS-31 on cardiac contractile function and infarct size in I/R
SS-31 (50 μM, P<0.01) administered at reperfusion also significantly
restored postreperfused cardiac contractile function parameters, LVDP, dP/dtmax,
and dP/dtmin, significantly compared to untreated I/R hearts. There was no
statistical significance between SS-31 (25, 50, 100 μM) and untreated I/R hearts
in the heart rate, coronary flow, LVESP, or LVEDP final values. Administration of
SS-31 (25, 50, 100 μM; P<0.01) at reperfusion significantly reduced infarct size
compared to untreated I/R hearts. Unexpectedly, the administration of the 25 and
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100 μM doses of SS-31 at reperfusion did not have significant restoration in
cardiac function compared to untreated I/R hearts, but there was a significant
decrease in infarct size in these I/R hearts (P<0.01). This anomaly could
potentially be attributed to reversible I/R-induced myocardial stunning. Reversibly
stunned myocardium is mechanically arrhythmic but could possibly regain
function at a later time. Dysfunction in viable cells could potentially be reversed,
whereas infarction is irreversible. Therefore, it is possible that cardiac function
could improve or decline at a time point beyond the time course recorded in this
study. This anomaly is consistent with the findings of a study investigating the
cardioprotective effects of Bendavia, an analogue of SS-31 and SS-02, in
myocardial I/R. The study found that treatment with Bendavia reduced infarct
size in guinea pig and sheep myocardial I/R models. However, there was no
effect on left ventricular output or arrhythmia score compared to untreated I/R
animals. It has been suggested that the surviving myocardium surrounding an
infarct may remain stunned for days to weeks following I/R(95). This explanation
may account for why the 25 and 100 µM doses of SS-31 did not significantly
improve post-reperfused cardiac function despite significantly decreasing infarct
size compared to untreated I/R controls(102). The results of the present study
suggest that mitochondrial ROS may be a significant contributor to myocardial
I/R injury, and inhibiting the release of mitochondrial ROS with selective
mitochondria-targeted antioxidants attenuates myocardial I/R injury and may
have a beneficial effect on subsequent cardiac contractile dysfunction.
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The efficacy of SS-31 has been attributed to its ability to become
selectively concentrated within mitochondria to scavenge ROS, whereas SS-20
is targeted to mitochondria but unable to scavenge ROS because lacks a Dmt
amino acid residue(18, 26, 103). Administration as a pretreatment followed by a
second treatment at reperfusion with SS-31 (i.p.), similar in dosage to the SS-31
that reduced blood H2O2 in an in vivo hind limb I/R model, was able to
significantly reduce infarct size, ventricular arrhythmias, and lipid peroxidation in
a rat myocardial I(60min)/R(60min) model in vivo(75, 99). A study using an ex
vivo guinea pig global myocardial I(30min)/R(90) model showed SS-31 is able to
prevent myocardial stunning when given throughout the experiment effectively,
and these results were later obtained with an SS-31 analog using an in vivo
myocardial I/R model(8, 73, 82, 104). The results from this study are unique in
that SS-31 was administered exclusively at reperfusion and still able to improve
infarct size and post-reperfused cardiac function; administration at the time of
reperfusion may be more clinically relevant in cases of patients experiencing
myocardial infarction(102). These results suggest that mitochondrial-derived
ROS is a significant contributing factor to myocardial stunning, and reduction in
mitochondrial ROS is cardioprotective. Similarly, SS-31 (2 mg/kg, i.p.)
administered at reperfusion in a mouse cerebral I(30min)/R(72h) model
significantly reduced infarct size compared to the untreated I/R brains(87, 105).
The activity of tert-butyl hydroperoxide, known to induce mitochondrial
depolarization and apoptosis by lipid peroxidation, was reduced in neuronal cell
lines also treated with SS-31. SS-31 also exhibited ROS-scavenging activity in
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the same neuronal cell lines(26). A subcuteaneous pretreatment, treatment at
reperfusion, and post treatment with SS-31 in a rat kidney I(30-45min)/R(24h)
model resulted in preserved mitochondrial structure and function as well as
reduced oxidative stress and inflammation following I/R(18). In hepatocytes
treated with hypochlorous acid, SS-31 was able to prevent cell death by inhibiting
an increase in mitochondrial SO and mitochondrial depolarization(106). SS-31
was also able to prevent an increase in mitochondrial SO due to induced shear
stress in endothelial cells(107). SS-31 has also been effective in a chronic model
of cardiac dysfunction by alleviating hypertensive cardiomyopathy. In the study,
SS-31 was able to significantly reduce angiotensin II-induced mitochondrial
oxidative stress, apoptosis signaling, and fibrosis(22). Furthermore, SS-31 is also
able to promote the activity of mitochondrial respiration and synthesis of ATP in
addition to its ability to scavenge ROS and attenuate ROS production and
mitochondrial swelling(108, 109).
Future Studies
To more clearly understand the role of mitochondrial-derived ROS in
contributing to myocardial I/R injury, direct measurements of mitochondrial ROS
at various I/R time points may allow clarification of the correlation between the
amount of ROS release and tissue damage in myocardial I/R. These types of
measurements may also quantify the efficacy of selectively mitochondrialtargeted antioxidants in reducing mitochondrial ROS release. In a similar way,
infarct size could be measured at more than one time point to confirm the ratio of
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tissue death that occurs during the reperfusion phase to the ischemic phase of
I/R. To supplement the infarct size data, histological staining for apoptosis
markers may be useful to confirm areas of cell death. No sham hearts in this
study were given SS-31 treatment, which may be a useful way to confirm
whether or not SS-31 itself alters cardiac function independently from I/R. Other
selectively mitochondrial-targeted antioxidants may also be used in a similar
myocardial I/R model. Additionally, eNOS uncoupling has been shown to
contribute to I/R injury by initiating endothelial dysfunction and increased ROS
release within 5-10 min of reperfusion(52, 53). Measurements of the eNOS dimer
to monomer ratio via western blotting of left ventricular tissue or high
performance liquid chromatography to detect the BH4 to BH2 ratio may be useful
in monitoring the degree of eNOS activity in myocardial I/R and understanding
the relationship between endothelial dysfunction and myocardial I/R injury.
For more effective translation into the clinical setting, the cardioprotective
effects of agents given at reperfusion need to be reproducible in multiple
laboratories, models, and species. One of the limitations of the isolated perfused
heart model is that there is a limited time course. Measurements of infarct size
and cardiac function at time points 24 hours or longer may be better predictors of
morbidity and mortality following acute myocardial infarction. I/R-induced
myocardial stunning may mask the potential function of postreperfused cardiac
tissue since stunning can be reversible. An in vivo regional I/R model could also
be used to confirm the results of a global ischemia model and obtain
measurements at later time points. Most studies of myocardial I/R use healthy,
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juvenile animals without comorbid conditions or varying nutritional or hormonal
status(5). Comorbid conditions, such as diabetes, hypertension,
hypercholesterolemia, and left ventricular hypertrophy, are commonly found in
the clinical setting and may impact the efficacy of cardioprotective
interventions(5, 110, 111). Patients in the clinical setting may also have been
exposed to transient periods of angina with a preconditioning effect, which can
skew the interpretation of how much of the cardioprotective effect can be
contributed to an intervention(5).
Significance of Findings
Selectively mitochondrial-targeted antioxidants administered at the time of
reperfusion in myocardial I/R exerted cardioprotective effects in this study. MitoQ
and SS-31 infused with autologous plasma at the beginning of reperfusion both,
independently, expeditiously and effectively restored postreperfused cardiac
contractile function and reduced infarct size. The results of this study suggest
that MitoQ and SS-31 may effectively reduce I/R injury during the treatment of
myocardial infarction or heart transplantation in the clinical setting, thus allowing
these patients to have a better quality of life attributable to better cardiac function
and more viable cardiac tissue following ischemic events.
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